The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Valuation Is Forecasted For The Methenamine Hippurate Tablets Market By 2030 Starting From Its 2026 Size?

The methenamine hippurate tablets market has seen substantial growth in recent years. It is anticipated to increase from $10.11 billion in 2025 to $10.86 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.4%. This historical growth can be attributed to several factors including limited awareness regarding recurrent UTI prevention, restricted access to specialized urology care, low adoption rates of antimicrobial tablets, reliance on hospital-based treatment, and traditional packaging formats.

The methenamine hippurate tablets market is projected to experience robust expansion over the coming years. By 2030, this market is anticipated to reach a valuation of $14.49 billion, expanding at a compound annual growth rate (CAGR) of 7.5%. Key factors driving this growth during the forecast period include the rising frequency of urinary tract infections, an increasing preference for outpatient and homecare treatment options, innovations in tablet formulation technology, the growing embrace of personalized medicine approaches, and the broadening reach of online pharmacy platforms. Significant trends expected to shape the market during this period encompass the escalating occurrence of recurrent UTIs, an expanding elderly demographic, a greater inclination towards oral antimicrobial treatments, the broadening scope of home healthcare provisions, and the development of tailored medication plans.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9412&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Methenamine Hippurate Tablets Market?

The methenamine hippurate tablets market is set to grow due to an increase in urinary tract infection (UTI) cases. UTIs are widespread conditions that develop when bacteria enter the urethra and infect the urinary tract, typically via the skin or rectum. Methenamine hippurate tablets are utilized to prevent or manage recurring urinary tract infections caused by specific bacteria. For instance, in October 2023, the National Health Service, a UK-based government department, reported 147,285 admissions where urinary tract infections (UTIs) were the primary diagnosis during the 2022-23 period. Of these, 56% (82,392) were individuals aged 65 and older, with the highest number of admissions, 17,280, occurring in the 80-84 age group. Thus, the increasing incidence of urinary tract infections is fueling the expansion of the methenamine hippurate market.

Methenamine Hippurate Tablets Market Driver: Rising Healthcare Expenditure Fuels The Market Growth

Which Segment Categories Define The Methenamine Hippurate Tablets Market?

The methenamine hippurate tablets market covered in this report is segmented –

1) By Type: 20 Tablets Or Bottle, 6 Tablets Or Bottle

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By Application: Uncomplicated UTIs, Healthcare-associated UTIs

4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Subsegments:

1) By 20 Tablets per Bottle: Standard Packaging, Bulk Packaging Options

2) By 6 Tablets per Bottle: Standard Packaging, Sample Or Trial Packaging

What Major Market Trends Are Driving Changes In The Methenamine Hippurate Tablets Market?

Leading companies active in the methenamine hippurate tablets market are forming collaborations to boost their market profitability. A strategic collaboration signifies a deliberate partnership between various entities, aimed at achieving common goals through synchronized efforts and by leveraging each other’s strengths and resources. For example, in May 2023, EQL Pharma AB, a Sweden-based pharmaceutical company that offers methenamine hippurate tablets, entered into a collaboration with Dr. Pfleger Arzneimittel GmbH. Through this partnership, EQL Pharma AB plans to introduce Methenamine Hippurate under an EQL-registered brand within the subsequent two years. This endeavor involves standard license fees, specific regulatory and reimbursement milestones, and a volume-dependent supply price, all subject to regulatory approval. Dr. Pfleger Arzneimittel GmbH is a Germany-based pharmaceutical company.

Who Are The Top Companies Competing In The Methenamine Hippurate Tablets Market?

Major companies operating in the methenamine hippurate tablets market are Alvogen Lux Holdings S.ÀR.L., Micro Labs Inc., Aurobindo Pharma, Amneal Pharmaceuticals Inc., Viatris Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Zydus Pharmaceuticals Ltd., Lupin Ltd., Alkem Laboratories Ltd., Ipca Laboratories Ltd., Granules India Ltd., Teva Pharmaceutical Industries Ltd., Apotex Pharmachem Inc., Sandoz International GmbH, Mylan Laboratories Ltd.

Read the full methenamine hippurate tablets market report here:

https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report

Which Regions Are Projected To Dominate The Methenamine Hippurate Tablets Market In The Coming Years?

North America was the largest region in the methenamine hippurate tablets market in 2025. The regions covered in the methenamine hippurate tablets market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Methenamine Hippurate Tablets Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9412&type=smp

Browse Through More Reports Similar to the Global Methenamine Hippurate Tablets Market 2026, By The Business Research Company

Methenamine Hippurate Tablets Market Report 2026

https://www.thebusinessresearchcompany.com/report/methenamine-hippurate-tablets-global-market-report

Methicillin Resistant Staphylococcus Aureus Mrsa Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-global-market-report

Muscle Relaxant Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/muscle-relaxant-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model